NR0B2 and metabolic dysfunction-associated steatohepatitis: Contrastively, the agonist effect of γ-MCA on FXR-activated SHP expression at both transcriptional (NASH vs. NASH + 100 mg/kg γ-MCA, p < 0.0001) and translational levels (NASH vs. NASH + 100 mg/kg γ-MCA, p = 0.0002) (Figure 6A–C).